Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Dr. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will now oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical time for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission to the U.S. Food and Drug Administration. According to the company, Dr. Fang has played a key role in advancing clinical development efforts and will lead scientific strategy through upcoming clinical and regulatory milestones.
Dr. Fang’s elevation to CSO underscores Annovis’ commitment to strengthening its leadership team as it nears a potential inflection point. The company’s buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing these underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s and Parkinson’s diseases.
Annovis is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on developing treatments for neurodegenerative diseases. The company’s lead candidate, buntanetap (formerly posiphen), has shown promise in earlier trials. The upcoming Phase 3 data and potential NDA submission represent significant milestones for the company and for patients with Alzheimer’s disease, a condition affecting millions worldwide with limited treatment options.
The announcement of Dr. Fang’s promotion was made via press release and can be accessed in full at https://ibn.fm/c9jdt. For more information about Annovis Bio, visit www.annovisbio.com and follow on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
